Subscribe To
Kalvista pharmaceuticals to present data at the 2023 annual scientific meeting of the american college of allergy, asthma & immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical compa...
November 2, 2023, 6:30 am
Hikma pharmaceuticals upgrades guidance for all segments except injectables
Hikma pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has upgraded its full-year guidance for two out of three...
November 2, 2023, 6:26 am
Reviva pharmaceuticals: positive results in phase 3 but the stock is back where it started
Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo o...
November 2, 2023, 3:11 am
Corvus pharmaceuticals announces publication of preclinical data demonstrating potential of itk inhibition with soquelitinib as a novel approach to t cell-mediated inflammatory and immune diseases
Data demonstrated soquelitinib was active in six inflammatory/immune disease models and provides rationale for development in a range of additional Th...
November 1, 2023, 11:31 pm
Tarsus to report third quarter 2023 financial results on thursday, november 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply pro...
November 1, 2023, 10:35 pm
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biop...
November 1, 2023, 8:27 pm
Ligand pharmaceuticals (lgnd) laps the stock market: here's why
In the most recent trading session, Ligand pharmaceuticals (LGND) closed at $53.30, indicating a +1.93%...
November 1, 2023, 7:32 pm
Ani pharmaceuticals (anip) stock drops despite market gains: important facts to note
ANI pharmaceuticals (ANIP) closed at $61.66 in the latest trading session, marking a -0.13% move from t...
November 1, 2023, 7:32 pm
Tarsus to report third quarter 2023 financial results on thursday, november 9, 2023
IRVINE, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply prov...
November 1, 2023, 6:35 pm
Olema oncology to participate in upcoming investor conferences in november
SAN FRANCISCO, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage bioph...
November 1, 2023, 4:27 pm
Amphastar pharmaceuticals to release third quarter earnings and hold conference call on november 8, 2023
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 1, 2023 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results f...
November 1, 2023, 4:10 pm
Xenon pharmaceuticals announces conference call and webcast to discuss third quarter 2023 financial results and provide corporate update
VANCOUVER, British Columbia, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Xenon pharmaceuticals Inc. (Nasdaq:XENE)...
November 1, 2023, 4:01 pm
Apellis pharmaceuticals, inc. (apls) q3 2023 earnings call transcript
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2023 Earnings Conference Call November 1, 2023 8:00 AM ET Company Participants Cedric Francois - Co-Fo...
November 1, 2023, 2:36 pm
Processa pharmaceuticals announces formation of oncology advisory board with renowned key opinion leaders
Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap...
November 1, 2023, 12:15 pm
Mgc pharmaceuticals clarifies share consolidation and new fundraise
MGC pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) has provided clarity on the company's consolidati...
November 1, 2023, 11:37 am
Is medpace (medp) outperforming other medical stocks this year?
Here is how Medpace (MEDP) and Acadia pharmaceuticals (ACAD) have performed compared to their sector so...
November 1, 2023, 11:21 am
Apellis pharmaceuticals reports third quarter 2023 financial results
Generated total revenues of $110.4 million in the third quarter, including $75.3 million for SYFOVRE® (pegcetacoplan injection) and $23.9 million for...
November 1, 2023, 11:05 am
Apellis pharmaceuticals, inc. (apls) reports q3 loss, tops revenue estimates
Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $0.84. This co...
November 1, 2023, 9:46 am
Atea pharmaceuticals to host third quarter 2023 financial results conference call on november 8, 2023
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged i...
November 1, 2023, 7:00 am
Gsk raises outlook amid strong demand for new rsv vaccine
GSK PLC (LSE:GSK, NYSE:GSK) said a strong third quarter performance has driven a further upgrade to full-year guidance boosted by demand for its respi...
November 1, 2023, 3:31 am